Macrogenics Inc. (MGNX) is a prominent biopharmaceutical company that primarily focuses on the discovery and development of innovative monoclonal antibody-based therapies for the treatment of a wide range of cancers. The company's key strategies involve using its powerful proprietary technology platforms to create novel antibodies with the help of genetically modified mice and human antibodies to develop effective cancer treatments.
Founded in 2000, Macrogenics is headquartered in Rockville, Maryland, USA. It is listed and publicly traded under the ticker symbol 'MGNX' on the NASDAQ. The company employs a workforce that is passionate about science and committed to saving lives and improving the health of people suffering from cancer.
Macrogenics' portfolio includes diverse immuno-oncology programs that include antibody-based therapeutics and bispecific molecules designed to target specific cancer cells. One of its most promising drug candidates is Margetuximab, an experimental monoclonal antibody for the treatment of patients with metastatic HER2-positive breast cancer. The drug can change the function of the immune system to attack cancer cells, thus offering a new potential treatment method for cancer patients.
The company is also known for its research collaborations and partnerships with major pharmaceutical players. This includes a deal with Incyte under which Macrogenics could potentially earn up to $900 million in milestone payments for the development, manufacturing, and commercialization of bispecific therapeutics.
Macrogenics is focused on creating breakthrough treatments for patients who have limited treatment options. The company has highly invested in research and development which forms the core foundation of its long-term growth. Despite obstacles such as clinical failures or regulatory setbacks, Macrogenics remains committed and resilient in its mission and vision.
While the biopharmaceutical industry is often characterized by high risks and high rewards, Macrogenics believes its approach of leveraging next-generation antibody technology, clinical expertise, and strategic partnerships gives the company a competitive edge, contributing to its steady progress in oncology and offering hope to the global patient population.
In conclusion, Macrogenics Inc. is a dynamic company striving to transform cancer care by aiming to discover, develop, and deliver to patients novel biopharmaceuticals for treating various types of cancer. The company's dedicated researchers and scientists work tirelessly to create breakthrough treatments that offer hope and improved health outcomes for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
MacroGenics (NASDAQ: MGNX) announced a 25% confirmed response rate in its interim Phase 2 LINNET trial for advanced clear cell gynecologic cancer, with four out of 16 evaluable patients responding to lorigerlimab. The company is enrolling an additional 20 patients at a lower dose due to significant treatment-related toxicity observed in the initial cohort, with updated results anticipated in the first half of 2027. Despite a 49% rate of severe treatment-related adverse events across the broader safety population, MacroGenics believes the data supports the promise of dual PD-1/CTLA-4 blockade for this underserved patient population.
MacroGenics, Inc. announced positive interim Phase 1 results for MGC026, a B7-H3-directed antibody-drug conjugate (ADC), showing durable responses across multiple tumor types and a manageable safety profile in patients with advanced solid tumors. Specifically, MGC026 demonstrated a 27% best overall response rate in heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients. Based on these encouraging findings, the company plans to initiate a front-line SCCHN combination study evaluating MGC026 with pembrolizumab in early 2027.
MacroGenics, Inc. has announced that the first patient has been dosed in its Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) targeting an undisclosed antigen in advanced solid tumors. This clinical trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MGC030. The company anticipates the study will provide deeper insights into how this molecule can address unmet needs for patients with specific solid tumors.
MacroGenics, Inc. announced the first patient has been dosed in its Phase 1 study of MGC030, a novel antibody-drug conjugate (ADC) for advanced solid tumors. MGC030, which targets an undisclosed antigen, has shown promising preclinical antitumor activity and is the company's third ADC in clinical development. The study aims to evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients with various relapsed or refractory solid cancers.